...
首页> 外文期刊>Molecular Carcinogenesis >Oroxylin a reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-κB signaling pathway
【24h】

Oroxylin a reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-κB signaling pathway

机译:Oroxylin a通过抑制NF-κB信号通路下调P-糖蛋白表达来逆转人肝癌BEL7402 / 5-FU细胞的多药耐药性

获取原文
获取原文并翻译 | 示例
           

摘要

In this study, oroxylin A showed strong reversal potency in BEL7402/5-FU cells and the reversal fold (RF) reached 4.69. Simultaneously, rhodamine-123 accumulation assay and flow cytometry analysis demonstrated oroxylin A could increase drug accumulation. When combined with oroxylin A, 5-FU showed inducing apoptosis effect more seriously in DAPI staining experiment. Moreover, the mRNA and protein expression of multi-drug resistance gene (MDR1) were also decreased by oroxylin A. Further experiments exhibited that oroxylin A can downregulate P-gp expression through inhibiting nuclear factor-κB (NF-κB) signaling pathway, which might be the mechanism of reversal resistance of oroxylin A. In summary, oroxylin A could be a good candidate for the development of new MDR reversal agent and its reversal mechanism probably due to the suppression of P-gp expression via inhibiting NF-κB signaling pathway.
机译:在这项研究中,oroxylin A在BEL7402 / 5-FU细胞中显示出强大的逆转能力,逆转倍数(RF)达到4.69。同时,若丹明-123积累测定和流式细胞仪分析表明,奥洛西林A可以增加药物积累。在DAPI染色实验中,5-FU与木犀草素A联合使用更能诱导细胞凋亡。此外,oroxylin A还降低了多药抗性基因(MDR1)的mRNA和蛋白表达。进一步的实验表明,oroxylin A可以通过抑制核因子-κB(NF-κB)信号传导通路来下调P-gp表达。综上所述,Oroxylin A可能是开发新的MDR逆转剂及其逆转机制的良好候选者,其原因可能是通过抑制NF-κB信号通路抑制了P-gp表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号